Albert Jan Bredenoord
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Albert Jan Bredenoord has a total of 480 co-authors. Here are the top co-authors by number of shared publications:
Andreas J. Smout
23 shared publicationsA. J. P. M. Smout
Department of Gastroenterology and Hepatology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
16 shared publications- André Smout
Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
10 shared publications - Froukje B. van Hoeij
Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands
9 shared publications - Joanne Verheij
Department of Pathology, UMC, University of Amsterdam, Cancer Center Amsterdam
9 shared publications - Boudewijn F. Kessing
Department of Gastroenterology and Hepatology, Academic Medical Center Amsterdam, Amsterdam, The Netherlands
7 shared publications
Latest Publications
- Open Access
- 15 November 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (11)
Development of a Brief Screening Tool for Adaptive Eating Behaviors in Adults With Eosinophilic Esophagitis
Patients with eosinophilic esophagitis (EoE) frequently adapt their eating behaviors to facilitate dysphagia. We evaluated their prevalence and their potential utility as a non‐invasive, ancillary indicator of histologic disease activity or stricture (HDAoS), as well as their association with health‐related quality of life (QoL) and persistence after achieving remission. Methods: In this cross‐sectional study, adult patients with EoE completed questionnaires assessing medical history, dysphagia, health‐related QoL, anxiety and depression sensitivity, and adaptive eating behaviors. Statistical analyses evaluated the prevalence of adaptive eating behaviors. Principal Component Analysis (PCA) was performed to identify behavioral clustering and derive a reduced screening set. Results: Among 151 patients (67% males, mean age 42 years) were included, 85% reported at least one adaptive eating behavior (median 3, IQR 1–4). Excessive chewing (57%), drinking during meals (46%), and prolonged meal times (47%) were most prevalent. Presence of adaptive eating behaviors was associated with more dysphagia ( p = 0.004) and anxiety ( p = 0.001) complaints, HDAoS ( p = 0.005), and lower health‐related QoL ( p = 0.001). The clustering of behaviors supported a four‐item screening set, TICS ( T urning away tablets or pills, I mbibing fluids, C hewing excessively, S ocial avoidance), as a potential ancillary indicator of HDAoS and QoL. Notably, 60% of participants continued these behaviors despite remission. Conclusion: Adaptive eating behaviors are highly prevalent in EoE and often persist despite remission, potentially reflecting ingrained coping mechanisms developed in response to chronic dysphagia, and its negative effect on QoL, or association with an increased risk of HDAoS, suggesting that TICS could provide valuable context during follow‐up, though prospective external validation is required.
- 15 November 2026
- Published by Wiley in Neurogastroenterology & Motility
- Vol. 38 (11)
Open AccessDevelopment of a Brief Screening Tool for Adaptive Eating Behaviors in Adults With Eosinophilic Esophagitis
Patients with eosinophilic esophagitis (EoE) frequently adapt their eating behaviors to facilitate dysphagia. We evaluated their prevalence and their potential utility as a non‐invasive, ancillary indicator of histologic disease activity or stricture (HDAoS), as well as their association with health‐related quality of life (QoL) and persistence after achieving remission. Methods: In this cross‐sectional study, adult patients with EoE completed questionnaires assessing medical history, dysphagia, health‐related QoL, anxiety and depression sensitivity, and adaptive eating behaviors. Statistical analyses evaluated the prevalence of adaptive eating behaviors. Principal Component Analysis (PCA) was performed to identify behavioral clustering and derive a reduced screening set. Results: Among 151 patients (67% males, mean age 42 years) were included, 85% reported at least one adaptive eating behavior (median 3, IQR 1–4). Excessive chewing (57%), drinking during meals (46%), and prolonged meal times (47%) were most prevalent. Presence of adaptive eating behaviors was associated with more dysphagia ( p = 0.004) and anxiety ( p = 0.001) complaints, HDAoS ( p = 0.005), and lower health‐related QoL ( p = 0.001). The clustering of behaviors supported a four‐item screening set, TICS ( T urning away tablets or pills, I mbibing fluids, C hewing excessively, S ocial avoidance), as a potential ancillary indicator of HDAoS and QoL. Notably, 60% of participants continued these behaviors despite remission. Conclusion: Adaptive eating behaviors are highly prevalent in EoE and often persist despite remission, potentially reflecting ingrained coping mechanisms developed in response to chronic dysphagia, and its negative effect on QoL, or association with an increased risk of HDAoS, suggesting that TICS could provide valuable context during follow‐up, though prospective external validation is required.
- 12 November 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
The role of high-resolution manometry in the assessment of altered foregut anatomy: scoping review and interpretation recommendations
Introduction: The Chicago Classification provides high-resolution manometry (HRM) criteria for the diagnosis of primary esophageal motility disorders but does not address HRM findings in patients with altered foregut anatomy or post-surgical states. Material and methods: We performed a scoping review of three databases to identify studies reporting HRM findings in altered foregut anatomy, including anti-reflux and bariatric surgery, treated achalasia, head and neck surgery, and rarer conditions such as esophageal diverticula and esophageal atresia. The aim was to synthesize available evidence and provide pragmatic recommendations for HRM interpretation in these conditions not addressed by the Chicago Classification. Results: We identified 168 articles addressing esophageal dysmotility associated with altered foregut anatomy or post-interventional states. Obesity, esophageal diverticula and esophageal strictures can all result in physiological changes in HRM metrics. HRM assesses motor function in hiatus hernia and identifies post-fundoplication outflow obstruction (PFOO) or junctional disruption. Bariatric procedures substantially alter esophagogastric junction anatomy, resulting in hypocontractile or obstructive manometric patterns. Unsuccessfully treated achalasia is defined by elevated IRP and obstruction on provocative maneuvers; the terms adequately treated achalasia (ATA) and treated achalasia with outflow obstruction (TAOO) have been proposed. Pseudo-achalasia is manometrically indistinguishable from primary achalasia. Other conditions including radiation therapy, head and neck surgery and treated esophageal atresia can result in heterogenous and often non-specific HRM findings. Conclusions: The Chicago Classification cannot be applied to motility patterns observed in patients with altered foregut anatomy or following foregut surgery. Instead, HRM interpretation in these settings should integrate anatomic information and focus on clinically actionable findings, particularly obstructive states.
- 12 November 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
The role of high-resolution manometry in the assessment of altered foregut anatomy: scoping review and interpretation recommendations
Introduction: The Chicago Classification provides high-resolution manometry (HRM) criteria for the diagnosis of primary esophageal motility disorders but does not address HRM findings in patients with altered foregut anatomy or post-surgical states. Material and methods: We performed a scoping review of three databases to identify studies reporting HRM findings in altered foregut anatomy, including anti-reflux and bariatric surgery, treated achalasia, head and neck surgery, and rarer conditions such as esophageal diverticula and esophageal atresia. The aim was to synthesize available evidence and provide pragmatic recommendations for HRM interpretation in these conditions not addressed by the Chicago Classification. Results: We identified 168 articles addressing esophageal dysmotility associated with altered foregut anatomy or post-interventional states. Obesity, esophageal diverticula and esophageal strictures can all result in physiological changes in HRM metrics. HRM assesses motor function in hiatus hernia and identifies post-fundoplication outflow obstruction (PFOO) or junctional disruption. Bariatric procedures substantially alter esophagogastric junction anatomy, resulting in hypocontractile or obstructive manometric patterns. Unsuccessfully treated achalasia is defined by elevated IRP and obstruction on provocative maneuvers; the terms adequately treated achalasia (ATA) and treated achalasia with outflow obstruction (TAOO) have been proposed. Pseudo-achalasia is manometrically indistinguishable from primary achalasia. Other conditions including radiation therapy, head and neck surgery and treated esophageal atresia can result in heterogenous and often non-specific HRM findings. Conclusions: The Chicago Classification cannot be applied to motility patterns observed in patients with altered foregut anatomy or following foregut surgery. Instead, HRM interpretation in these settings should integrate anatomic information and focus on clinically actionable findings, particularly obstructive states.
- Open Access
- 30 October 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (4) , 607-614
Reflux and Other Esophageal Acidification Patterns in Achalasia Patients With Reflux Esophagitis After Peroral Endoscopic Myotomy
Elise M. Wessels, Niek Warringa, Gwen M. C. Masclee, Pietro Familiari, and Albert J. Bredenoord. J Neurogastroenterol Motil 2026;32:607-14. https://doi.org/10.5056/jnm26006
- 30 October 2026
- Published by The Korean Society of Neurogastroenterology and Motility in Journal of Neurogastroenterology and Motility
- Vol. 32 (4) , 607-614
Open AccessReflux and Other Esophageal Acidification Patterns in Achalasia Patients With Reflux Esophagitis After Peroral Endoscopic Myotomy
Elise M. Wessels, Niek Warringa, Gwen M. C. Masclee, Pietro Familiari, and Albert J. Bredenoord. J Neurogastroenterol Motil 2026;32:607-14. https://doi.org/10.5056/jnm26006
- Open Access
- 4 September 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Thymic Stromal Lymphopoietin as a Therapeutic Target for the Treatment of Eosinophilic Esophagitis
Thymic stromal lymphopoietin (TSLP) is a key upstream epithelial cytokine, and its overexpression is associated with inflammation, leading to immune dysfunction, epithelial barrier disruption, and tissue remodeling. TSLP is implicated in the pathogenesis of multiple atopic diseases, including asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis (EoE). EoE is a chronic, type 2 (T2) inflammatory disease linked to a delayed-type hypersensitivity response to food antigens and characterized by eosinophil-predominant mucosal inflammation and esophageal dysfunction. TSLP expression and TSLP-mediated T2 inflammatory activity are elevated in esophageal biopsies in patients with active EoE compared with patients with inactive EoE and healthy individuals. In phase 3 clinical trials, a monoclonal antibody against TSLP, called tezepelumab, has shown significant improvements in clinical outcomes compared with placebo in other atopic conditions that have a shared T2 inflammatory disease pathology and epithelial remodeling pathway with EoE, such as asthma and chronic rhinosinusitis with nasal polyps. In this review, we present evidence of TSLP involvement in mediating and exacerbating EoE pathology and discuss how targeting TSLP activity could be a viable therapeutic option for EoE treatment.
- 4 September 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Open AccessThymic Stromal Lymphopoietin as a Therapeutic Target for the Treatment of Eosinophilic Esophagitis
Thymic stromal lymphopoietin (TSLP) is a key upstream epithelial cytokine, and its overexpression is associated with inflammation, leading to immune dysfunction, epithelial barrier disruption, and tissue remodeling. TSLP is implicated in the pathogenesis of multiple atopic diseases, including asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis (EoE). EoE is a chronic, type 2 (T2) inflammatory disease linked to a delayed-type hypersensitivity response to food antigens and characterized by eosinophil-predominant mucosal inflammation and esophageal dysfunction. TSLP expression and TSLP-mediated T2 inflammatory activity are elevated in esophageal biopsies in patients with active EoE compared with patients with inactive EoE and healthy individuals. In phase 3 clinical trials, a monoclonal antibody against TSLP, called tezepelumab, has shown significant improvements in clinical outcomes compared with placebo in other atopic conditions that have a shared T2 inflammatory disease pathology and epithelial remodeling pathway with EoE, such as asthma and chronic rhinosinusitis with nasal polyps. In this review, we present evidence of TSLP involvement in mediating and exacerbating EoE pathology and discuss how targeting TSLP activity could be a viable therapeutic option for EoE treatment.
- 22 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (11) , 5711-5719
Results of Laparoscopic Heller Myotomy in Achalasia Patients with Persistent or Recurrent Symptoms After Peroral Endoscopic Myotomy (POEM)
Introduction Peroral endoscopic myotomy (POEM) is an effective and safe treatment for achalasia. However, in some patients symptoms may persist or recur, requiring additional treatment. The aim of this study was to examine the efficacy and safety of performing laparoscopic Heller myotomy (LHM) in achalasia patients having persistent or recurrent symptoms after POEM. Methods This retrospective study includes patients who underwent LHM after they failed on POEM, which was performed between August 2011 and March 2024. Follow-up data were extracted from hospital medical records, and patients completed questionnaires regarding achalasia symptoms and quality of life between March 2024 and August 2025. Primary outcome was treatment success after LHM, defined as Eckardt score ≤ 3 without subsequent retreatment. Results In total, 22 patients were included (median age 43 years, 50.0% female) of which 21 completed questionnaires. Median follow-up time after LHM in patients who previously failed on POEM was 86 months. Treatment success was observed in three patients (13.6%, n = 3/22), with follow-up of 36, 74 and 110 months after LHM. A marked decline in success rate of LHM following POEM was observed over time: approximately 70% after one year and 30% after two years. For patients with treatment failure after LHM, 73.7% required retreatment (n = 14/19), predominantly with pneumatic dilation. Conclusion LHM following POEM yields only minimal benefit with a rapid loss of success over time. These outcomes suggest limited clinical value of LHM following POEM failure and indicate that alternative strategies may be preferable.
- 22 July 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (11) , 5711-5719
Results of Laparoscopic Heller Myotomy in Achalasia Patients with Persistent or Recurrent Symptoms After Peroral Endoscopic Myotomy (POEM)
Introduction Peroral endoscopic myotomy (POEM) is an effective and safe treatment for achalasia. However, in some patients symptoms may persist or recur, requiring additional treatment. The aim of this study was to examine the efficacy and safety of performing laparoscopic Heller myotomy (LHM) in achalasia patients having persistent or recurrent symptoms after POEM. Methods This retrospective study includes patients who underwent LHM after they failed on POEM, which was performed between August 2011 and March 2024. Follow-up data were extracted from hospital medical records, and patients completed questionnaires regarding achalasia symptoms and quality of life between March 2024 and August 2025. Primary outcome was treatment success after LHM, defined as Eckardt score ≤ 3 without subsequent retreatment. Results In total, 22 patients were included (median age 43 years, 50.0% female) of which 21 completed questionnaires. Median follow-up time after LHM in patients who previously failed on POEM was 86 months. Treatment success was observed in three patients (13.6%, n = 3/22), with follow-up of 36, 74 and 110 months after LHM. A marked decline in success rate of LHM following POEM was observed over time: approximately 70% after one year and 30% after two years. For patients with treatment failure after LHM, 73.7% required retreatment (n = 14/19), predominantly with pneumatic dilation. Conclusion LHM following POEM yields only minimal benefit with a rapid loss of success over time. These outcomes suggest limited clinical value of LHM following POEM failure and indicate that alternative strategies may be preferable.
- 15 April 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (5)
Sleep positional therapy for patients with systemic sclerosis and nighttime gastroesophageal reflux symptoms
- 15 April 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (5)
Sleep positional therapy for patients with systemic sclerosis and nighttime gastroesophageal reflux symptoms
- 7 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (05) , 465-466
Next step for antireflux mucosal ablation
10.1055/a-2740-9297 Over the past 25 years, several endoscopic antireflux devices have been introduced, but have usually been withdrawn a few years later because of disappointing efficacy, severe complications, or both [1]. These devices can be roughly divided into three different categories: endoscopic injection of barrier reinforcements at the lower esophageal sphincter (LES) level (Gatekeeper, Enteryx); endoscopic suturing techniques (Esophyx/TIF, Endocinch, MUSE, Overstitch); and techniques that alter the gastroesophageal junction (GEJ) by creating fibrosis (Stretta). Most of these innovations were driven by industry and included complex equipment to enhance the antireflux barrier. What the techniques also have in common is that most studies consisted of open-label prospective case series with relatively short follow-up and soft primary end points, such as reduction in proton pump inhibitor (PPI) use. It is no surprise that these studies usually presented favorable first results, which then led to disappointment in subsequent clinical use or better designed controlled studies, or to the devices being withdrawn after serious complications. Antireflux mucosectomy (ARMS) was introduced as a technique that used endoscopic mucosal resection (EMR) in the cardia to induce fibrosis and change the shape of the GEJ [2]. It differed from the previously mentioned endoscopic antireflux techniques as it was introduced by academic endoscopists and does not require expensive dedicated equipment. Antireflux mucosal ablation (ARMA) is quite similar to ARMS, but uses argon plasma coagulation instead of EMR to induce scarring around the cardia [3]. In contrast to other endoscopic antireflux techniques, ARMA seems relatively easy to perform and only standard endoscopic equipment is required; because of this it has more potential to change the treatment landscape. High quality studies of the technique were however lacking. Chavan et al. are therefore to be congratulated for designing and performing the randomized sham-controlled trial with inclusion of relevant end points that is published in this issue of Endoscopy [4]. It is these kinds of studies that drive the field forward. An impressive result was seen on the primary end point of the study, the gastroesophageal reflux disease health-related quality-of-life (GERD-HRQL) score. Furthermore, acid exposure time, total number of reflux episodes, reflux esophagitis, Hill’s grading, and PPI use were all reduced in the patients undergoing ARMA. The broad improvement of reflux parameters not seen in the patients treated with a sham procedure suggests a real effect. Is ARMA therefore ready for widespread dissemination in clinical practice? The most relevant question would be, for which kind of patients would this treatment be suited? The results of this trial showed that the acid exposure time was reduced from 3.0% to 2.2% and acid reflux episodes were reduced from 78 to 35 per 24 hours, which is a clear improvement but rather modest compared with the magnitude of effect that PPIs have on acid reflux. Most patients with GERD therefore seem to be better off with a PPI. However, while PPIs change only the acidity of the reflux episodes, ARMA also reduces the number of nonacid reflux episodes, resulting in a reduction in the total number of reflux episodes (from 102 to 45 / 24 hours). ARMA could therefore be beneficial for those patients who have an inadequate response to PPIs due to symptoms resulting from persistent nonacid reflux. Compared with a fundoplication, which reduces the number of reflux episodes from 90 to 7 per 24 hours, these results are however modest [5]. Also, ARMA does not restore a hiatal hernia, which also excludes most patients with severe GERD. For those patients with more severe GERD, antireflux surgery therefore remains more appropriate, but there is a subgroup of patients that have persistent symptoms on PPIs and are not willing or not eligible to undergo antireflux surgery. The authors indeed selected a very mild GERD phenotype, with a physiological acid exposure and mostly an absence of reflux esophagitis. Two-thirds of the patients fell into the category of reflux hypersensitivity and one-third had functional heartburn. Such patients often have a poor response to PPIs as their symptoms result in part from hypervigilance. In these patients, PPIs just take the acidic aspect of the reflux trigger away and a remaining sensation of gastric contents flowing into the esophagus is still present. The authors have demonstrated that ARMA could be beneficial in this subgroup. This is convenient as, despite the low acid exposure, these patients often experience their symptoms as very severe and are poor candidates for antireflux surgery owing to their higher chance of developing postoperative symptoms of gas-bloat and dysphagia. On the other hand, it is surprising that a reflux-reducing treatment such as ARMA provided symptomatic relief in patients with functional heartburn, as these are patients in whom there is no evidence at all that their symptoms are caused by gastroesophageal reflux. Furthermore, ARMA seemed to result in a greater reduction in nonacid reflux than in acid reflux, which has not been seen in previous studies. An explanation for this seemingly selective antireflux behavior of the GEJ is not provided and cannot be explained by the reduction in transient LES relaxations seen with ARMS [6]. It is also not clear from the manuscript when and how patients were unblinded, or whether they could have become unblinded during the study as the symptomatic improvement was much larger than the objective improvements. Furthermore, GERD is a mild and chronic disease for which alternatives exist and long-term efficacy and safety data of any intervention is therefore required before its widespread implementation. Finally, this is a dynamic field with the introduction of new techniques following quickly, such as the recently reported antireflux mucoplasty (ARMP) technique [7]. It therefore begs the question which technique should become the preferred option. In conclusion, in diseases in which symptoms are the main determinant and a substantial placebo effect is present, sham-controlled studies are indispensable to determine the effect of endoscopic interventions. Too often we have encountered positive data from uncontrolled series describing endoscopic interventions that have disappeared completely in a subsequent sham-controlled study [8]. With their current study, Chavan at al. have made a significant step in the right direction for ARMA. Article published online: 07 January 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 7 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 58 (05) , 465-466
Next step for antireflux mucosal ablation
10.1055/a-2740-9297 Over the past 25 years, several endoscopic antireflux devices have been introduced, but have usually been withdrawn a few years later because of disappointing efficacy, severe complications, or both [1]. These devices can be roughly divided into three different categories: endoscopic injection of barrier reinforcements at the lower esophageal sphincter (LES) level (Gatekeeper, Enteryx); endoscopic suturing techniques (Esophyx/TIF, Endocinch, MUSE, Overstitch); and techniques that alter the gastroesophageal junction (GEJ) by creating fibrosis (Stretta). Most of these innovations were driven by industry and included complex equipment to enhance the antireflux barrier. What the techniques also have in common is that most studies consisted of open-label prospective case series with relatively short follow-up and soft primary end points, such as reduction in proton pump inhibitor (PPI) use. It is no surprise that these studies usually presented favorable first results, which then led to disappointment in subsequent clinical use or better designed controlled studies, or to the devices being withdrawn after serious complications. Antireflux mucosectomy (ARMS) was introduced as a technique that used endoscopic mucosal resection (EMR) in the cardia to induce fibrosis and change the shape of the GEJ [2]. It differed from the previously mentioned endoscopic antireflux techniques as it was introduced by academic endoscopists and does not require expensive dedicated equipment. Antireflux mucosal ablation (ARMA) is quite similar to ARMS, but uses argon plasma coagulation instead of EMR to induce scarring around the cardia [3]. In contrast to other endoscopic antireflux techniques, ARMA seems relatively easy to perform and only standard endoscopic equipment is required; because of this it has more potential to change the treatment landscape. High quality studies of the technique were however lacking. Chavan et al. are therefore to be congratulated for designing and performing the randomized sham-controlled trial with inclusion of relevant end points that is published in this issue of Endoscopy [4]. It is these kinds of studies that drive the field forward. An impressive result was seen on the primary end point of the study, the gastroesophageal reflux disease health-related quality-of-life (GERD-HRQL) score. Furthermore, acid exposure time, total number of reflux episodes, reflux esophagitis, Hill’s grading, and PPI use were all reduced in the patients undergoing ARMA. The broad improvement of reflux parameters not seen in the patients treated with a sham procedure suggests a real effect. Is ARMA therefore ready for widespread dissemination in clinical practice? The most relevant question would be, for which kind of patients would this treatment be suited? The results of this trial showed that the acid exposure time was reduced from 3.0% to 2.2% and acid reflux episodes were reduced from 78 to 35 per 24 hours, which is a clear improvement but rather modest compared with the magnitude of effect that PPIs have on acid reflux. Most patients with GERD therefore seem to be better off with a PPI. However, while PPIs change only the acidity of the reflux episodes, ARMA also reduces the number of nonacid reflux episodes, resulting in a reduction in the total number of reflux episodes (from 102 to 45 / 24 hours). ARMA could therefore be beneficial for those patients who have an inadequate response to PPIs due to symptoms resulting from persistent nonacid reflux. Compared with a fundoplication, which reduces the number of reflux episodes from 90 to 7 per 24 hours, these results are however modest [5]. Also, ARMA does not restore a hiatal hernia, which also excludes most patients with severe GERD. For those patients with more severe GERD, antireflux surgery therefore remains more appropriate, but there is a subgroup of patients that have persistent symptoms on PPIs and are not willing or not eligible to undergo antireflux surgery. The authors indeed selected a very mild GERD phenotype, with a physiological acid exposure and mostly an absence of reflux esophagitis. Two-thirds of the patients fell into the category of reflux hypersensitivity and one-third had functional heartburn. Such patients often have a poor response to PPIs as their symptoms result in part from hypervigilance. In these patients, PPIs just take the acidic aspect of the reflux trigger away and a remaining sensation of gastric contents flowing into the esophagus is still present. The authors have demonstrated that ARMA could be beneficial in this subgroup. This is convenient as, despite the low acid exposure, these patients often experience their symptoms as very severe and are poor candidates for antireflux surgery owing to their higher chance of developing postoperative symptoms of gas-bloat and dysphagia. On the other hand, it is surprising that a reflux-reducing treatment such as ARMA provided symptomatic relief in patients with functional heartburn, as these are patients in whom there is no evidence at all that their symptoms are caused by gastroesophageal reflux. Furthermore, ARMA seemed to result in a greater reduction in nonacid reflux than in acid reflux, which has not been seen in previous studies. An explanation for this seemingly selective antireflux behavior of the GEJ is not provided and cannot be explained by the reduction in transient LES relaxations seen with ARMS [6]. It is also not clear from the manuscript when and how patients were unblinded, or whether they could have become unblinded during the study as the symptomatic improvement was much larger than the objective improvements. Furthermore, GERD is a mild and chronic disease for which alternatives exist and long-term efficacy and safety data of any intervention is therefore required before its widespread implementation. Finally, this is a dynamic field with the introduction of new techniques following quickly, such as the recently reported antireflux mucoplasty (ARMP) technique [7]. It therefore begs the question which technique should become the preferred option. In conclusion, in diseases in which symptoms are the main determinant and a substantial placebo effect is present, sham-controlled studies are indispensable to determine the effect of endoscopic interventions. Too often we have encountered positive data from uncontrolled series describing endoscopic interventions that have disappeared completely in a subsequent sham-controlled study [8]. With their current study, Chavan at al. have made a significant step in the right direction for ARMA. Article published online: 07 January 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 1 November 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (6)
Long-term treatment in eosinophilic esophagitis: continue, taper, or stop?
- 1 November 2025
- Published by Oxford University Press (OUP) in Diseases of the Esophagus
- Vol. 38 (6)
Long-term treatment in eosinophilic esophagitis: continue, taper, or stop?
- Open Access
- 1 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
A multicenter, retrospective cohort study on the diagnosis, treatment and natural history of eosinophilic gastrointestinal disorders in the Netherlands
Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Diseases (non-EoE EGIDs) are poorly understood. Evaluate clinical manifestations, diagnostics and treatment of non-EoE EGIDs at four hospitals in the Netherlands from 1991 to 2019. For this retrospective cohort study, centralized nationwide network and registry for cyto- and histopathology in the Netherlands (PALGA) was used. Seventy patients consented to participate. Median duration of follow up was 26 months, and median age was 36 years. About 44% had eosinophilic colitis (EoC) and 30% had > 1 GI location (multisite EGID). Most patients (91%) had mucosal type, 6% muscular and 3% serosal EGID. Three patients (4%) did not have follow up. Relapsing remitting in 21% (14/67) patients, with most being multisite (43%; 9/21). Single flares in 57% and chronically symptomatic in 22% of population. Concomitant atopy was seen in 29%. Normal endoscopy results in 61%; ileum was commonly identified normal area. Partial or complete symptom improvement to treatment seen in 71%. Results of the longitudinal retrospective Dutch study do not show progression from single site to multisite EGID or change in EGID type. We conclude that identifying patients requires further research as majority of patients had normal endoscopy and vague abdominal symptoms.
- 1 March 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-10
Open AccessA multicenter, retrospective cohort study on the diagnosis, treatment and natural history of eosinophilic gastrointestinal disorders in the Netherlands
Non-Eosinophilic Esophagitis Eosinophilic Gastrointestinal Diseases (non-EoE EGIDs) are poorly understood. Evaluate clinical manifestations, diagnostics and treatment of non-EoE EGIDs at four hospitals in the Netherlands from 1991 to 2019. For this retrospective cohort study, centralized nationwide network and registry for cyto- and histopathology in the Netherlands (PALGA) was used. Seventy patients consented to participate. Median duration of follow up was 26 months, and median age was 36 years. About 44% had eosinophilic colitis (EoC) and 30% had > 1 GI location (multisite EGID). Most patients (91%) had mucosal type, 6% muscular and 3% serosal EGID. Three patients (4%) did not have follow up. Relapsing remitting in 21% (14/67) patients, with most being multisite (43%; 9/21). Single flares in 57% and chronically symptomatic in 22% of population. Concomitant atopy was seen in 29%. Normal endoscopy results in 61%; ileum was commonly identified normal area. Partial or complete symptom improvement to treatment seen in 71%. Results of the longitudinal retrospective Dutch study do not show progression from single site to multisite EGID or change in EGID type. We conclude that identifying patients requires further research as majority of patients had normal endoscopy and vague abdominal symptoms.